166 results on '"Selmaj, Krzysztof"'
Search Results
2. Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials and an Open-label Extension Trial (P2-6.007)
3. Safety Patterns over Time with Ozanimod During an Open-label Extension Trial in Patients with Relapsing Multiple Sclerosis (P10-6.012)
4. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
5. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
6. Relapse Rate and Time to First Relapse Were Improved With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients With Relapsing Multiple Sclerosis (RMS) (P1-1.Virtual)
7. Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (P6-4.010)
8. Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) (P6-4.005)
9. Evaluating No Evidence of Disease Activity in Patients With Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 RADIANCE and Open-Label Extension Studies of Ozanimod (P7-4.012)
10. Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: Primary data from the Phase III Antelope study (P6-4.003)
11. Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies (P5-4.009)
12. Efficacy and safety of ublituximab versus teriflunomide in relapsing multiple sclerosis: Results of the Phase 3 ULTIMATE I and II trials (4494)
13. Treatment Satisfaction in Patients with Highly-active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis (1925)
14. Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis (RMS) Patients from the Phase 3 ASCLEPIOS I and II Trials (1300)
15. Onset of Action of Ozanimod for MRI Outcomes in Patients With Relapsing Multiple Sclerosis (4265)
16. Cases of COVID-19 in Alemtuzumab-Treated Patients With MS: Pharmacovigilance Report (2059)
17. Outcomes in Alemtuzumab-Treated Patients With Thyroid Adverse Events: 6-Year Pooled CARE-MS Data (1509)
18. Low Rate of Infections With Long-term Use of Ozanimod in Relapsing Multiple Sclerosis Trials (1596)
19. B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials (2356)
20. Alemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in RRMS Patients: CARE-MS II Follow-up (TOPAZ Study) (151)
21. Circular RNA of Blood Leukocytes Contribute To Proinflammatory Changes in Relapsing-Remitting Multiple Sclerosis (S55.005)
22. Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) (P3.2-037)
23. Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS II (TOPAZ Study) (P3.2-058)
24. Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096)
25. Ozanimod Efficacy in Relapsing Multiple Sclerosis Supported by Open-Label Long-Term Extension of Two Phase 3 Trials (P3.2-036)
26. Long-term effects of fingolimod in multiple sclerosis
27. Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM) (P3.396)
28. Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005)
29. Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study (P6.390)
30. Clinical and Magnetic Resonance Imaging Results From RADIANCE Part B, a Multicenter, Randomized, Double-Blind, Phase 3 Trial of Ozanimod Versus Intramuscular Interferon β-1a in Relapsing Multiple Sclerosis (RMS) (P3.410)
31. Durable Clinical Outcomes With Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (P6.369)
32. Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.006)
33. Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) (P6.376)
34. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
35. Early Fingolimod Treatment Improves Disease Outcomes at 2 and 4 years in Patients with Relapsing-Remitting Multiple Sclerosis (P6.332)
36. Clinical and optical coherence tomography outcome in secondary progressive multiple sclerosis patients after autologous mesenchymal stem cells intrathecal transplantation. (P6.403)
37. No Evidence of Disease Activity on Ocrelizumab Treatment in Patients With Early Relapsing Multiple Sclerosis: Pooled Analysis of the Phase III OPERA Studies (P4.391)
38. Efficacy and Safety of Ozanimod: Results From the 2-Year Blinded Extension of RADIANCE, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Relapsing Multiple Sclerosis (S24.008)
39. Aberrant profile of serum exosomal miRNA and peripheral blood cells secretion of exosomes in RR MS (P1.401)
40. Efficacy of Ocrelizumab on Brain MRI Outcomes in Patients with Early Relapsing Multiple Sclerosis: Pooled Analysis of the OPERA Studies (P6.338)
41. Efficacy and Safety of Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 Study (P5.338)
42. Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) (S24.006)
43. The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics (P6.344)
44. Ofatumumab versus teriflunomide in relapsing MS: adaptive design of two Phase 3 studies (ASCLEPIOS I and ASCLEPIOS II) (S16.005)
45. Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I) (S24.005)
46. Safety and Tolerability of Opicinumab in Relapsing Multiple Sclerosis: the Phase 2b SYNERGY Trial (P5.369)
47. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
48. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
49. Treatment-Naive Patients with Active RRMS Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I Study (S51.004)
50. Patients Who Discontinued SC IFNB-1a and Switched to Alemtuzumab in the CARE-MS II Extension Study Show Durable Reduction in New Lesion Activity (P3.025)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.